BioXcel Therapeutics announced that it has achieved 33% enrollment in its 200-patient SERENITY At-Home trial, a pivotal Phase 3 study assessing the safety of BXCL501, an orally dissolving film ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback